Persistence Market Research Blog

Posts tagged ‘Biological Drugs Industry’

Global Biological Drugs Market: North America to Witness Highest Growth by 2020

Biological drugs are typically derived from living cells and are used in treatment of various diseases such as cancer, blood-related diseases, auto-immune diseases and other medical disorders. Biological drugs have more complex structure than conventional drugs. These are highly sensitive and more difficult to characterize and produce. A biological drug typically has around 250 in-process tests during manufacturing compared to about 50 tests for a conventional drug.

The global market of biological drugs is categorized based on therapeutic protein, mAb and vaccines. The therapeutic protein segmentation is further sub-segmented into Enbrel, Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen, Levemir, Victoza, Betaseron, Neupogen, and Eylea.  The mAb segment comprises Humira, Remicade, Rituxan, Avastin, Herceptin and Lucentis. The vaccine segment is further sub-segmented into Prevnar 13, Gardasil, Fluzone, Varivax and Cervarix.

In terms of geography, North America has the largest market share followed by Europe and Asia in the global biological drugs market. Increased usage of biological drugs for the treatment of diseases, such as cancer, diabetes and other chronic diseases, are supporting the growth of the biological drugs market in the North American region. For instance, in 2012, the American College of Rheumatology, an organization that advances rheumatology through education and research, recommended biologic agents and disease modifying antirheumatic drugs for the treatment of rheumatoid arthritis.

Read complete report at


Tag Cloud